As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price target of $314. The recent selloff has pushed the stock “near floor valuation levels,” says the analyst, who believes competitive headwinds to the company’s core cardiopulmonary franchises are now fully-reflected in the stock’s multiple.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics upgraded to Neutral from Underperform at BofA
- United Therapeutics to present 10 posters, presentations at USHLT
- Buy Recommendation for United Therapeutics: Undervalued Potential in IPF Treatment with Tyvaso
- United Therapeutics price target lowered to $314 from $328 at BofA
- Positive Outlook for United Therapeutics Amidst Competitive Landscape and Growth Initiatives